TY - JOUR
T1 - Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL
AU - Kameda, Kazuaki
AU - Kako, Shinichi
AU - Kim, Sung Won
AU - Usui, Yoshiaki
AU - Kato, Koji
AU - Fukuda, Takahiro
AU - Uchida, Naoyuki
AU - Kobayashi, Hikaru
AU - Wakayama, Toshio
AU - Sakaida, Emiko
AU - Yano, Shingo
AU - Imada, Kazunori
AU - Nara, Miho
AU - Ikeda, Takashi
AU - Fuchida, Shin ichi
AU - Ishikawa, Jun
AU - Sugahara, Hiroyuki
AU - Kanda, Junya
AU - Kimura, Takafumi
AU - Ichinohe, Tatsuo
AU - Atsuta, Yoshiko
AU - Kondo, Eisei
N1 - Funding Information:
Conflicts of interest disclosure: K. Kato is a consultant for, and has received research funding from AbbVie, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Eisai, and Novartis; is a consultant for AstraZeneca; has received honoraria and research funding from Bristol-Myers Squibb, Kyowa Kirin, and Ono; is a consultant and has received honoraria and research funding from Celgene, Janssen; has received honoraria from Sumitomo Dainippon Pharma Co., Ltd., NSD, Mundi, outside the submitted work. K.I. has received honoraria from Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Novartis Pharma K.K., Celgene Co., Ltd., Bristol-Myers Squibb K.K., Takeda Pharmaceutical Co. Ltd., Nippon Shinyaku Co., Ltd., Otuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., and Sumitomo Dainippon Pharma Co., Ltd., outside the submitted work. S.F. has received honoraria from Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Sanofi, Bristol-Myers Squibb Co., Ltd., and Celgene Co., Ltd., outside the submitted work. T.I. reports research funding from Astellas Pharma, Chugai Pharmaceutical Co., CSL Behring, Eisai Co., FUJIFILM Wako Chemicals., Kyowa Kirin Co., Ono Pharmaceutical Co., Pfizer, Nippon Shinyaku Co., Abbvie, Otsuka Pharmaceutical Co., Repertoire Genesis Inc., Sumitomo Dainippon Pharma Co., Taiho Pharmaceutical Co., Takara Bio Inc., Takeda Pharmaceutical Co., and Zenyaku Kogyo Co., honoraria from Bristol-Myers Squibb, Celgene, Janssen Pharmaceutical K.K., Kyowa Kirin Co., Takeda Pharmaceutical Co., CSL Behring, Astellas Pharma, Eisai Co., Novartis, FUJIFILM Wako Chemicals., Nippon Shinyaku Co., and Repertoire Genesis Inc., outside the submitted work. E.K. has received honoraria from Takeda Pharmaceutical Co and Sumitomo Dainippon Pharma Co, outside the submitted work. The remaining authors declare no competing financial interests.
Funding Information:
This work was supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from the Japan Agency for Medical Research and Development, AMED (19ek0510023h) (to Y.A.), Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (20J14747), Jichi Medical University Graduate Student Research Award 2021, and Japan Leukemia Research Award (to K. Kameda).
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/5
Y1 - 2022/5
N2 - Fit patients with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) in relapsed or refractory (R/R) disease status often receive salvage chemotherapy followed by autologous hematopoietic stem cell transplantation (autoHCT) or allogeneic HCT (alloHCT). However, there is no consensus on the type of HCT that should be applied for such patients. Herein, we retrospectively evaluated the survival outcome of 760 adult R/R PTCL-NOS or AITL patients who underwent the first HCT. Among them, 318 relapsed after first remission (REL) and 442 were refractory to the primary therapy (PIF). The 4-year overall survival (OS) of autoHCT and alloHCT was 50 and 50% for REL patients, and 52 and 49% for PIF patients, respectively. In the multivariable analysis, alloHCT tended to be associated with better progression-free survival (PFS) in REL (hazard ratio [HR] 0.74; 95% confidence interval [CI]: 0.53–1.03), and significantly better PFS in PIF (HR 0.64; 95% CI: 0.46–0.88) compared with autoHCT. The subgroup analysis with propensity-score matching showed that alloHCT was associated with better OS for REL-sensitive and PIF-nonremission disease. This study suggested that the advantage of alloHCT for R/R PTCL-NOS or AITL is different, depending on the disease status at HCT.
AB - Fit patients with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) in relapsed or refractory (R/R) disease status often receive salvage chemotherapy followed by autologous hematopoietic stem cell transplantation (autoHCT) or allogeneic HCT (alloHCT). However, there is no consensus on the type of HCT that should be applied for such patients. Herein, we retrospectively evaluated the survival outcome of 760 adult R/R PTCL-NOS or AITL patients who underwent the first HCT. Among them, 318 relapsed after first remission (REL) and 442 were refractory to the primary therapy (PIF). The 4-year overall survival (OS) of autoHCT and alloHCT was 50 and 50% for REL patients, and 52 and 49% for PIF patients, respectively. In the multivariable analysis, alloHCT tended to be associated with better progression-free survival (PFS) in REL (hazard ratio [HR] 0.74; 95% confidence interval [CI]: 0.53–1.03), and significantly better PFS in PIF (HR 0.64; 95% CI: 0.46–0.88) compared with autoHCT. The subgroup analysis with propensity-score matching showed that alloHCT was associated with better OS for REL-sensitive and PIF-nonremission disease. This study suggested that the advantage of alloHCT for R/R PTCL-NOS or AITL is different, depending on the disease status at HCT.
UR - http://www.scopus.com/inward/record.url?scp=85127264517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127264517&partnerID=8YFLogxK
U2 - 10.1038/s41375-022-01545-w
DO - 10.1038/s41375-022-01545-w
M3 - Article
C2 - 35347237
AN - SCOPUS:85127264517
SN - 0887-6924
VL - 36
SP - 1361
EP - 1370
JO - Leukemia
JF - Leukemia
IS - 5
ER -
